What is anti-HIgG(Fab)-N-DM1 ADC?

This ADC comprises a Fab fragment of an anti-human IgG specific polyclonal antibody conjugated via a noncleavable linker to DM1. DM1 is a cytotoxic molecule that binds to tubulins, disrupting microtubule dynamics and inducing cell death.

What are the primary experimental applications of anti-HIgG(Fab)-N-DM1 ADC?

This ADC is utilized primarily in cancer research, particularly for targeting cells that express specific antigens recognized by the human IgG Fab fragment. It can be used to study the efficacy of targeted drug delivery and the apoptotic pathways induced by tubulin disruption.

How can anti-HIgG(Fab)-N-DM1 ADC be used to assess the efficacy of novel therapeutic targets?

Researchers can utilize this ADC to assess the expression and accessibility of novel therapeutic targets on cancer cells. By tracking the efficacy of DM1-induced cell death in cells expressing these targets, researchers can validate the potential of these targets for further therapeutic development.

What experimental models are best suited for testing the anti-HIgG(Fab)-N-DM1 ADC?

The ADC is particularly suitable for use in in vitro cell culture models that express the target antigens and in vivo animal models where the human IgG Fab fragment has high affinity for the tumor antigens. These models help in evaluating the specificity and therapeutic potential of the ADC.

Can the anti-HIgG(Fab)-N-DM1 ADC be used to study resistance mechanisms in cancer therapy?

Yes, this ADC can be employed to study the development of resistance mechanisms in cancer cells, such as changes in antigen expression or modifications in microtubule sensitivity to DM1. Understanding these mechanisms can help in designing more effective ADCs and combination therapies.

Home
Products
Anti-Ab ADCs
IgG Fab
anti-HIgG(Fab)-N-DM1 ADC

anti-HIgG(Fab)-N-DM1 ADC (CAT#: ADC-AA-018)

This ADC product is comprised of an anti-human IgG Fab specific polyclonal antibody conjugated via a noncleavable linker to DM1. The antibody portion is a secondary antibody and the drug portion, DM1, is a cytotoxic small molecule which binds to tubulins, interrupts microtubule dynamics, and induces cell death. This product displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening human monoclonal antibodies as ADC candidates.

ADC Target
ADC Antibody
ADC Linker
ADC payload drug

Name
IgG Fab

Overview
The fragment antigen-binding (Fab) fragment is a region on an antibody that binds to antigens. It is composed of one constant and one variable domain of each of the heavy and the light chain. The variable domain contains the paratope (the antigen-binding site), comprising a set of complementarity determining regions, at the amino terminal end of the monomer. Each arm of the Y thus binds an epitope on the antigen

Overview
anti-human IgG Fab specific polyclonal IgG antibody

Species Reactivity
Human

Name
Noncleavable linkers

Description
Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.

Name
DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)

Description
Derived from Maytansinoid,a group of cytotoxins structurally similar to rifamycin, geldanamycin, and ansatrienin. The eponymous natural cytotoxic agent maytansine is a 19-member lactam (ansa
macrolide) structure originally isolated from the Ethiopian shrub Maytenus ovatus. Maytansinoids can bind to tubulin at or near the vinblastine-binding site, which interfere the formation of microtubules and depolymerize already formed microtubules, inducing mitotic arrest in the intoxicated cells.

For Research Use Only. NOT FOR CLINICAL USE.

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform

Reviews

Literature

Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-AA-018. Click the button above to contact us or submit your feedback about this product.

Customer Reviews FAQ

Excellent

Anti-HIgG(Fab)-N-DM1 ADC offers unparalleled precision in targeting microtubules. This product's efficacy in inducing cell death while minimizing toxicity is exceptional.

Excellent

Creative Biolabs' anti-HIgG(Fab)-N-DM1 ADC is groundbreaking. Its ability to disrupt microtubule dynamics precisely without primary antibodies simplifies our pre-screening process.

Excellent

Impressed by the delivery mechanism of this ADC! The noncleavable linker ensures DM1 remains effective, providing consistent results in our cytotoxicity assays.

Excellent

Reliable and potent, the Anti-HIgG(Fab)-N-DM1 ADC targets cancer cells effectively, demonstrating significant results in microtubule disruption and subsequent cell death.

Excellent

A robust tool for monoclonal antibody screening. Anti-HIgG(Fab)-N-DM1 ADC's precise binding and potent cell-killing capacity make it indispensable for our research.

Q: 1: What is anti-HIgG(Fab)-N-DM1 ADC?
A: This ADC comprises a Fab fragment of an anti-human IgG specific polyclonal antibody conjugated via a noncleavable linker to DM1. DM1 is a cytotoxic molecule that binds to tubulins, disrupting microtubule dynamics and inducing cell death.
Q: 2: What are the primary experimental applications of anti-HIgG(Fab)-N-DM1 ADC?
A: This ADC is utilized primarily in cancer research, particularly for targeting cells that express specific antigens recognized by the human IgG Fab fragment. It can be used to study the efficacy of targeted drug delivery and the apoptotic pathways induced by tubulin disruption.
Q: 3: How can anti-HIgG(Fab)-N-DM1 ADC be used to assess the efficacy of novel therapeutic targets?
A: Researchers can utilize this ADC to assess the expression and accessibility of novel therapeutic targets on cancer cells. By tracking the efficacy of DM1-induced cell death in cells expressing these targets, researchers can validate the potential of these targets for further therapeutic development.
Q: 4: What experimental models are best suited for testing the anti-HIgG(Fab)-N-DM1 ADC?
A: The ADC is particularly suitable for use in in vitro cell culture models that express the target antigens and in vivo animal models where the human IgG Fab fragment has high affinity for the tumor antigens. These models help in evaluating the specificity and therapeutic potential of the ADC.
Q: 5: Can the anti-HIgG(Fab)-N-DM1 ADC be used to study resistance mechanisms in cancer therapy?
A: Yes, this ADC can be employed to study the development of resistance mechanisms in cancer cells, such as changes in antigen expression or modifications in microtubule sensitivity to DM1. Understanding these mechanisms can help in designing more effective ADCs and combination therapies.

Quick Links

ADC Toxins

Drug-linker Complexes

Customized ADCs

Anti-Ab ADCs

Other Products

Same Target Same Linker Same Payload

CAT#	Product Name	Linker	Payload
ADC-AA-017	anti-HIgG(Fab)-C-MMAE ADC	Cleavable linkers	MMAE (Monomethyl auristatin E)
ADC-AA-064	Anti-HIgG(Fab)-C-MMAF ADC	Cleavable linkers	MMAF
ADC-AA-063	Anti-HIgG(Fab)-N-MMAF ADC	Noncleavable linkers	MMAF

CAT#	Product Name	Linker	Payload
ADC-AA-026	anti-MIgG(Fc)-N-DM1 ADC	Noncleavable linkers	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-037	anti-RIgG(HL)Fab-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-046	anti-Rat IgG(HL)Fab-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-045	anti-Rat IgG(HL)-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-034	anti-RIgG(HL)-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)

CAT#	Product Name	Linker	Payload
ADC-AA-008	anti-HIgG(Fc)-N-DM1 ADC	Noncleavable linkers	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-495	Anti-EGFR-SMCC-DM1 ADC-4	SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate)	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-487	Anti-CD70-MCC-DM1 ADC	MCC (Maleimidomethyl cyclohexane-1-carboxylate)	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-496	Anti-EGFR-SMCC-DM1 ADC	SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate)	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-572	Anti-ERBB2 (Trastuzumab-Fab)-SPP-DM1 ADC	SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate)	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)

Online Inquiry

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.